Oxford BioMedica’s TroVax phase I/II trial yields encouraging results

A poster was presented by the clinical investigators in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium on 23 February 2017 in Orlando, USA.

The poster described the open-label Phase I/II clinical trial involving 53 patients with inoperable, metastatic colorectal cancer who were randomised to receive either no treatment, low dose CPM, TroVax only or low dose CPM followed by TroVax.

The primary study endpoint was to assess increased anti-5T4 responses after treatment on day 43 and the secondary endpoints were progression free /overall survival and anti-5T4 responses over the trial period.

The study findings demonstrated that significant anti-5T4 immune responses were generated at treatment day 43. Secondary analysis revealed that both CPM and TroVax independently induced highly beneficial anti-tumour immune responses, resulting in significant survival of end stage colorectal cancer patients, without any major toxicity.

This was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients.

Oxford BioMedica CEO John Dawson said: “The presentation by the Clinical Investigators of the Phase I/II TaCTiCC study at the ASCO-SITC Clinical Immuno-Oncology symposium showed the potential benefit that Oxford BioMedica’s immunotherapy (TroVax) treatment could give to patients with advanced colorectal cancer.”